ALGORAE Aktie

 

Algorae launches second AOS2 synergy program with Peter MacCallum Cancer Centre's VCFG; 24 drug combos across cancers; six-month preclinical data....

Algorae inks Cadila deal to market two cardio/metabolic generics in Australia & NZ; Cadila develops/manufactures; AlgoraeRx handles regulatory and marketing....

Algorae Pharmaceuticals (ASX: 1AI) advances AlgoraeOS validation and signs Dr Reddy's distribution, signals near-term oncology revenue and stronger balance sheet....

Algorae Pharmaceuticals (ASX: 1AI) has identified 90 high-quality drug-combination candidates following a preliminary review of newly delivered in silico synergy predictions generated by its upgraded AlgoraeOS v2 platform....

Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre....

Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy's Laboratories to supply chemotherapy medicine capecitabine to the Australian market....

Algorae Pharmaceuticals (ASX: 1AI), in collaboration with the UNSW and CSIRO, has launched a major upgrade to its AlgoraeOS AI-driven platform for the discovery of drug combinations....

Algorae Pharmaceuticals (ASX: 1AI) has reported a period of significant expansion as it broadens its operations to include complementary commercial activities. In the three months to end September, the company advanced its dual-track strategy of AI-driven innovation and pharmaceutical commercialisation, securing two landmark deals to expand its presence across Australia and New Zealand. Algorae also advanced […] The post Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation appeared first on Small Caps....

Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […] The post Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership appeared first on Small Caps....

Algorae Pharmaceuticals (ASX: 1AI) has entered into an exclusive licencing agreement with Indian pharmaceutical manufacturer Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets. The products will be marketed under the Algorae brand to meet the needs of the combined market, which analysts value at approximately $10 million per […] The post Algorae Pharmaceuticals to Launch Five New Oncology Medicines in Australia-New Zealand Markets appeared first on Small Caps....

Algorae Pharmaceuticals (ASX:1AI) has this week signed a major exclusive commercial licensing…...

Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne's Peter MacCallum Cancer Centre. The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug […] The post Algorae Pharmaceuticals Advances Validation for Oncology-Focused Predictive Drug Combinations appeared first on Small Caps....

CA37640A4028 CA67010X1042 AU0000373722 CA29385B1094 CA83569N2077 DK0060816148 GB00BS3D4G58 JE00BRJ8YF63 SE0005731833 SE0012481570 AU000000APA1 AU0000033946 CA00654D2095 CA4315022026 CA45083C1086 GB00BDFGGK53 GB00BMTV7393 GG00BGDYDZ69 SE0016101844 SE0017885379 AU000000SPL0 AU000000WLD8 CA0813791096 CA3804732079 CA60306F1018 AU000000MFG4 AU0000296022 CA53044R8839 CA56658A4019 SE0020388932 AU000000OLI4 CA03820A1093 CA15234A4000 CA30222R1091 CA0037351073 CA15850F1053 CA31773B5018 CA41138T1057 CA72703G2027 CA98402E2069 CNE1000003R8 JP3889200006 AU000000SSM2 SE0015658570 CA30336V1031 CA3060442074 CA3194101067 CA8552811017 IT0001469995 SE0003491562 CA45250A4063 CA7759041055 SE0000396061 AU000000ACR3 CA53680T1021 CA68237A1093 CA69867J1057 FI4000233317 SE0009921588 CA09076M1014 CA38217M1005 FR0012596468 GB00BD5JRP64 AU000000EPM8 AU0000317976 CA05455X2059 NO0010081235 SE0011311554 SE0022240115 SE0023439500 AU0000372054 CA00289A1093 CA01559R4008...

The ASX200 closed x% at x points. In the Green Algorae Pharmaceuticals…...

Algorae Pharmaceuticals (ASX: 1AI) has partnered with the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre in Melbourne to validate AI-predicted drug synergies using high-throughput screening. The companies will conduct a study to confirm the efficacy of drug combinations and dose ranges across four distinct cancer cell lines including glioblastoma, pancreatic […] The post Algorae Pharmaceuticals teams with Peter MacCallum Centre to validate AI-predicted cancer drug synergies appeared first on Small Caps....

Algorae Pharmaceuticals (ASX: 1AI) has reported continued advancements to its proprietary Algorae Operating System (or AlgoraeOS) artificial intelligence (AI) drug discovery platform since it was officially launched in September. The AI-driven innovation has identified 24 novel drug targets in the past seven months, focusing on high-impact oncology indications such as breast cancer, leukaemia and glioblastoma. […] The post Algorae Pharmaceuticals strengthens drug pipeline as AlgoraeOS Version 2.0 development continues appeared first on Small Caps....

Algorae Pharmaceuticals (ASX: 1AI) has strengthened its leadership team with the appointment of seasoned pharmaceutical executive Vishal Shah to the role of chief commercial officer. Mr Shah has over 20 years' experience in the pharmaceuticals, biotechnology and healthcare industries. He will spearhead Algorae's commercial strategy to accelerate growth and expansion into complementary pharmaceutical market segments. […] The post Algorae Pharmaceuticals strengthens leadership team with appointment of new chief commercial officer appeared first on Small Caps....

Algorae Pharmaceuticals (ASX: 1AI) has received a tax rebate of $451,359 from the Australian Taxation Office (ATO) for eligible research and development (R&D) activities conducted during the 2023 and 2024 financial years. The rebate falls under a federally administered tax incentive program available to different industries with the aim of shaping Australia's economic future and […] The post Algorae Pharmaceuticals to use R&D tax rebate to advance AI-driven drug discovery programs appeared first on Small Caps....